Amarin, Elan in Parkinson's deal

ELN granted AMRN exclusive U.S. marketing rights to Permax pergolide, a dopamine receptor agonist marketed for Parkinson's disease. Permax had U.S. sales of about $40 million in 2000, AMRN said. Addit...